Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus MILI.
CHLOROMYXIN vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category C
Category C
Antibiotic
Antibiotic